Mike Cusnir, MD
Chief, Division of Hematology & Oncology
Codirector, Gastrointestinal Malignancies
Assistant Professor
Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center
New York, NY
Peers & Perspectives in Oncology: What was learned from the recent phase 3 ARANOTE trial (NCT04736199) data?
CUSNIR: This study was presented this year just after the data cutoff…. It’s not [fully] mature yet. ARANOTE, which was the last study [of an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)], was a very simple 2:1 [randomization] study of single-agent [darolutamide (Nubeqa)] plus ADT vs placebo plus ADT. In my view, this is the last study we’re going to be able to…